Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zorifertinib - AstraZeneca

Next Previous
Drug Profile

Zorifertinib - AstraZeneca

Alternative Names: AZD-3759; Zorifer; Zorifertinib hydrochloride - AstraZeneca

Latest Information Update: 21 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Alpha Biopharma; AstraZeneca
  • Class Amines; Antineoplastics; Piperazines; Quinazolines; Small molecules
  • Mechanism of Action ErbB receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Cancer metastases; Non-small cell lung cancer

Most Recent Events

  • 06 Jul 2026 Alpha Biopharma initiates a phase I trial (In volunteers) in China (PO) (NCT07620951)
  • 03 Jun 2026 Alpha Biopharma plans a phase I trial (In volunteers) in China (PO) in June 2026 (NCT07620951)
  • 24 Apr 2026 Alpha Biopharma in collaboration with Chinese Academy of Medical Sciences plans a phase II trial for Non-small cell lung cancer (Second-line therapy or greater, Combination therapy, Late-stage disease) in China in May 2026 (PO) (NCT07551414)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top